The term “epigenetic” is used to refer to heritable alterations in chromatin that are not due to changes in DNA sequence. Different growth factors and vascular genes mediate the angiogenic process, which is regulated by epigenetic states of genes. The aim of this article is to analyze the role of epigenetic mechanisms in the control and regulation of tumor angiogenetic processes. The reversibility of epigenetic events in contrast to genetic aberrations makes them potentially suitable for therapeutic intervention. In this context, DNA methyltransferase (DNMT) and HDAC inhibitors indirectly—via the tumor cells—exhibit angiostatic effects in vivo, and inhibition of miRNAs can contribute to the development of novel anti‐angiogenesis therapies.

中文翻译：

---

肿瘤血管生成的表观遗传控制。

术语“表观遗传的”用于指不是由于DNA序列的改变而引起的染色质的可遗传改变。不同的生长因子和血管基因介导血管生成过程，该过程由基因的表观遗传状态调节。本文的目的是分析表观遗传机制在控制和调节肿瘤血管生成过程中的作用。与遗传畸变相反，表观遗传事件的可逆性使其潜在地适于治疗干预。在这种情况下，DNA甲基转移酶（DNMT）和HDAC抑制剂通过肿瘤细胞间接发挥体内血管抑制作用，而抑制miRNA可以促进新型抗血管生成疗法的发展。